Replies to post #237723 on Biotech Values

[dewophile]

I just found it interesting they highlighted just 3 programs. The theme was speed of development starting w covid (then not mentioning any of the oncology mRNA programs) and going to their assets w best success/potential
Sometimes assets are omitted for competitive purposes of course (eg ABT’s HCV program went under the radar a long time)

[DewDiligence]

PFE returns Bavencio commercial rights to Merck KGaA in return for 15% royalty on sales:

https://www.emdgroup.com/en/news/oncology-27-03-2023.html

PFE booked $271M in Bavencio alliance revenue in 2022, which is a pretty small amount for a PD-(L)1 drug. Moreover, PFE has a subcutaneous PD-1, Sasanlimab, in its wholly-owned pipeline (#msg-163133643).